20th Feb 2009 10:00
|
For immediate release |
20 February 2009 |
ABCAM PLC
("Abcam" or "the Company")
Notification of Interim Results
Abcam plc (AIM: ABC), the rapidly growing bioscience company that markets antibodies via its own online catalogue, will announce its interim results for the six months ended 31 December 2008 on Tuesday 10 March 2009.
An analyst meeting will be held at 11am on Tuesday 10 March 2009 at the offices of Buchanan Communications, 45 Moorfields, London EC2Y 9AE.
For further information please contact:
|
Abcam |
+ 44 (0) 1223 696000 |
|
Jonathan Milner, Chief Executive Officer |
|
|
Jeff Iliffe, Chief Financial Officer |
|
|
www.abcam.com |
|
|
Numis Securities |
+ 44 (0) 20 7776 1500 |
|
Nominated Adviser: Michael Meade/ Nick Westlake |
|
|
Corporate Broking: James Black |
|
|
Buchanan Communications |
+ 44 (0) 20 7466 5000 |
|
Mark Court / Mary-Jane Johnson / Stasa Filiplic |
Notes for editors
About Abcam plc
Abcam is a producer and distributor of research-grade antibodies headquartered in Cambridge, UK, with a US office located in Cambridge, Massachusetts and a Japanese office in Tokyo. Abcam was admitted to AIM in November 2005 and trades under the ticker symbol ABC. The Company produces and distributes its own and third party produced antibodies to academic and commercial users throughout the world with product information provided and ordering available through the Company's website, www.abcam.com. The antibodies are sold under the Abcam brand name. The Company's vision is to build the largest online antibody resource in the world while also ensuring that the antibodies are of high quality and commercially viable. Abcam now has an online catalogue of over 47,000 products, most of which are antibodies, from over 250 suppliers supported by up-to-date and detailed technical data sheets, which are created by the Company. The Company currently employs over 200 staff in its three operating companies.
Related Shares:
ABC.L